ProfessorGisliJenkins

His clinical and research focus is on interstitial lung disease, and pulmonary fibrosis in particular. There are three major themes of his research. 1) Understanding the functional consequences of genetic risk factors for the development and progression of pulmonary fibrosis. 2) Using pre-clinical models of disease to try and therapeutically manipulate molecular pathways to prevent the development or progression of fibrosis. 3) Undertaking detailed assessment of patient cohorts with fibrotic disease (the PROFILE and INJUSTIS studies) or potentially fibrotic disease (the UKILD Post COVID study) to understand the risk factors and biomarkers that may predict the development of repair or fibrosis.

He completed his medical training at University of Southampton before undertaking postgraduate training in respiratory medicine in London. During this time he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from University College London before doing post-doctoral studies at University of California at San Francisco funded by an ARC Clinician Scientist Fellowship. 

In 2005 he returned to the UK as Clinical Senior Lecturer at the University of Nottingham where he established the Academic Interstitial Lung Disease Unit. He was the pulmonary fibrosis work package lead for the MRC Nottingham Molecular Pathology Node, and the Nottingham Biomedical Research Centre. He is currently the Familial Pulmonary Fibrosis lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine and is the Post Hospitalisation (PHOSP)-COVID study Fibrosis Working Group lead and leads the UK Interstitial Lung Disease consortium.

He has been the joint Editor-in-Chief of the official journal of the British Thoracic Society since 2015. He was chair of the British Thoracic Society Science and Research Committee from 2016-2018. He has also sat on a number of American Thoracic Society Committees and is co-Chair of the International Colloquium of Lung and Airway Fibrosis.

He is a founding Trustee of the patient charity Action for Pulmonary Fibrosis and is the clinical lead for the James Lind Alliance Priority Setting Partnership.

In 2021 he moved to Imperial College, London to lead the Margaret Turner Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute.

• 1) Fadista J, Kraven LM, Karjalainen J,   Andrews SJ,   Geller F,  Baillie JK,  Wain LV,  Jenkins RG,  Feenstra B. Shared genetic etiology between idiopathic pulmonary fibrosis and COVID-19 severity. MedRxiv. https://doi.org/10.1101/2020.12.15.20248279 EBioMedicine 2021 Mar 10;65:103277. doi: 10.1016/j.ebiom.2021.103277.
• 2) Goodwin AT, John AE; Joseph C, Habgood A, Tatler AL, Offermanns S, Henderson NC, Jenkins G. Stretch Regulates Alveologenesis Via Mesenchymal Gαq/11-Mediated TGFβ2 Activation BioRxiv 2020 doi; https://10.1101/2020.09.06.284778 
• 3) Drake, T; Docherty, A; Harrison, E; Quint, J; Adamali, H; Agnew, S ; Babu, S; Barber, C; Barratt, S; Bendstrup, E; Bianchi, S; Castillo, D; Chaudhuri, N; Chua, F; Coker, R; Chang, W; Crawshaw, A; Crowley, L; Dosanjh, D; Fiddler, C; Forrest, I; George, P; Gibbons, M; Groom, K; Haney, S; Hart, S; Heiden, E; Henry, M; Ho, LP; Hoyles, R; Hutchinson, J; Hurley, K; Jones, M; Jones, S; Kokosi, M; Kreuter, M; Mackay, L; Mahendran, S; Margaritopoulos, G; Molina-Molina, M; Molyneaux, P; O'Brien, A; O'Reilly, K; Packham, A; Parfrey, H; Poletti, V; Porter, J; Renzoni, E; Rivera-Ortega, P; Russell, AM; Saini, G; Spencer, L; Stella, G; Stone, H; Sturney, S; Thickett, D; Thillai, M; Wallace, T; Ward, K; Wells, A; West, A; Wickremasinghe, M; Woodhead, F; Hearson, G; Howard, L; Openshaw, P; Baillie, JK; Semple, M; Stewart, I; Jenkins, RG. Outcome of hospitalisation for COVID-19 in Interstitial Lung Disease patients: A multicentre study. MedRxiv07.15.20152967; doi: https://doi.org/10.1101/2020.07.15.20152967. Am J Respir Crit Care Med 2020 Oct 2. doi: 10.1164/rccm.202007-2794OC.
• 4) Dhindsa RS, Mattsson J, Nag A, Wang Q, Wain LV, Allen R,  Wigmore EM, Ibanez K, Vitsios D, Deevi SVV, Wasilewski S, Karlsson M,  V Lassi G, Olsson H,  Muthas D, Mackay A,  Murray L,  Young S,  Haefliger C, FinnGen Consortium,  Maher TMM,  Belvisi MG, Jenkins G,  Molyneaux P,  Platt A,  Petrovski S. Identification of a novel missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. bioRxiv06.29.178079v1 doi: https://doi.org/10.1101/2020.06.29.178079.
• 5) Khan F, Fabbri L, Stewart I, Robinson K, Smyth AR, Jenkins G. A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections medRxiv 04.23.20076612; doi: https://doi.org/10.1101/2020.04.23.20076612. Thorax Feb 12:thoraxjnl-2020-215266. doi: 10.1136/thoraxjnl-2020-215266.
• 6) Singh SJ, Barradell AC, Greening NJ, Bolton CE, Jenkins G, Preston L, Hurst JR. The British Thoracic Society survey of rehabilitation to support recovery of the Post Covid -19 population. medRxiv05.07.20094151; doi: https://doi.org/10.1101/2020.05.07.20094151. BMJ Open 2020 Dec 2;10(12):e040213. doi: 10.1136/bmjopen-2020-040213.
• 7) Leavy OC, Ma SF, Molyneaux PL, Maher TM, Oldham JM, Flores C, Noth I, Jenkins RG, Dudbridge F, Wain LV, Allen RJ. Proportion of Idiopathic Pulmonary Fibrosis Risk Explained by Known Common Genetic Loci in European Populations. Am J Respir Crit Care Med. 2020 Nov 23. doi: 10.1164/rccm.202008-3211LE
• 8) Molyneaux PL, Smith JJ, Saunders P, Chua F, Wells AU, Renzoni EA, Nicholson AG, Fahy WA, Jenkins RG, Maher TM. Bronchoalveolar Lavage is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. Am J Respir Crit Care Med. 2020 Aug 28. doi: 10.1164/rccm.202004-1138LE.
• 9) Aguiar JA, Tremblay BJ, Mansfield MJ, Woody O, Lobb B, Banerjee A, Chandiramohan A, Tiessen N, Cao Q, Dvorkin-Gheva A, Revill S, Miller MS, Carlsten C, Organ L, Joseph C, John A, Hanson P, Austin R, McManus BM, Jenkins G, Mossman K, Ask K, Doxey AC, Hirota JA. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur Respir J. 2020 Jul 16:2001123. doi: 10.1183/13993003.01123-2020.
• 10) Stewart ID, Nanji H, Figueredo G, Fahy WA, Maher TM, Moeller AJ, Ask K, Kolb M, Jenkins RG, Circulating fibrocytes can distinguish poor prognosis in pulmonary fibrosis. medRxiv 06.05.20123406; doi: https://doi.org/10.1101/2020.06.05.20123406 ERJ accepted
• 11) John AE, Graves RH, K. Pun T, Vitulli G, Forty EJ, Mercer PF, Morrell JL, Barrett JW, Hafeji M, Bibby LI, Gower E, Morrison VS, Boyce SH, Man Y, Anderson NA, Fallon BJ, Pritchard JM, Sollis SL, Le J, Gudmann NS, Leeming DJ, Flint DJ, Pyne S, Maher TM, Fisher AJ, Chambers RC, Lukey PT, Marshall RP, Macdonald SJF, Jenkins RG*, Slack RJ*. Discovery of a novel inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis. Nat Comms August 2020 doi:10.1038/s41467-020-18397-6
• 12) Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan K, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins* RG, Wain LV*. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201905-1017OC.
• 13) Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, Garman N, Costa M, Kendrick S, Onega M, Listanco A, Davies J, Ramada-Magalhaes J, Moz S, Fahy W, Maher TM, Jenkins GJ, Passchier J, Marshall RP. Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med 2020 Apr;47(4):967-979. doi: 10.1007/s00259-019-04586-z.
• 14) Jennifer T Cairns, Anthony Habgood, Rochelle C Edwards-Pritchard, Chloe Wilkinson, Iain D Stewart, Jack Leslie, Burns C Blaxall, Katalin Susztak, Siegfried Alberti, Alfred Nordheim, Fiona Oakley, R Gisli Jenkins, Amanda L Tatler. Loss of ELK1 has differential effects on age-dependent organ fibrosis and integrin expression. BioRxiv 2019 doi: https://doi.org/10.1101/755694 Int J Biochem and Cell Biol. 2020 Mar;120:105668
• 15) Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, O'Neal WK, Newell JD Jr, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM; COPDGene Investigators, ECLIPSE Investigators, SPIROMICS Research Group, and UK ILD Consortium.Overlap of Genetic Risk Between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Jul 24. doi: 10.1164/rccm.201903-0511OC. [Epub ahead of print]
• 16) Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019 Jul 17. pii: S2213-2600(19)30255-3. doi: 10.1016/S2213-2600(19)30255-3. [Epub ahead of print].
• 17) Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, Braybrooke R, Molyneaux PL, North B, Karkera Y, Leeming DJ, Karsdal MA, Nanthakumar CB, Fahy WA, Marshall RP, Jenkins RG, Maher TM. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res. 2019 Jul 12;20(1):148. doi: 10.1186/s12931-019-1118-7.
• 18) Khan F, Stewart I, Howard L, McKeever TM, Jones S, Hearson G, Braybrooke R, Edwards C, Jenkins G, Saini G. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. BMJ Open Respir Res. 2019 Jun 4;6(1):e000439. doi: 10.1136/bmjresp-2019-000439. eCollection 2019.
• 19) Lorenzo-Salazar JM, Ma SF, Jou J, Hou PC, Guillen-Guio B, Allen RJ, Jenkins RG, Wain LV, Oldham JM, Noth I, Flores C. Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing. ERJ Open Res. 2019 Jun 10;5(2). pii: 00071-2019. doi: 10.1183/23120541.00071-2019. eCollection 2019 Apr. PMID: 31205927
• 20) Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.
• 21) Dudbridge F, Allen RJ, Sheehan NA, Schmidt AF, Lee JC, Jenkins RG, Wain LV, Hingorani AD, Patel RS. Adjustment for index event bias in genome-wide association studies of subsequent events. Nat Commun. 2019 Apr 5;10(1):1561. doi: 10.1038/s41467-019-09381-w.
• 22) Stewart I, McKeever T, Braybrooke R, Oballa E, Simpson JK, Maher TM, Marshall RP, Lukey PT, Fahy WA, Jenkins G, Saini G. Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort. Eur Respir J. 2019 May 9;53(5). pii: 1801925. doi: 10.1183/13993003.01925-2018. Print 2019 May. PMID: 30846471
• 23) Bengs S, Becker E, Busenhart P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, Scharl M. β6 -integrin serves as a novel serum tumor marker for colorectal carcinoma. Int J Cancer. 2019 Aug 1;145(3):678-685. doi: 10.1002/ijc.32137. Epub 2019 Jan 29.
• 24) Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial. BMJ Open Respir Res. 2018 Aug 20;5(1):e000325. doi: 10.1136/bmjresp-2018-000325. eCollection 2018.
• 25) Maher TM, Oballa E, Simpson J, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG. Identification of an epithelial biomarker signature in Idiopathic Pulmonary Fibrosis: an analysis from the prospective multicentre PROFILE study. The Lancet Respir Med. 2017 Nov 14. pii: S2213-2600(17)30430-7. doi: 10.1016/S2213-2600(17)30430-7.
• 26) Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, Guillen-Guio B, Ma SF, Okamoto T, John AE, Obeidat M, Yang IV, Henry A, Hubbard RB, Navaratnam V, Saini G, Thompson N, Booth HL, Hart SP, Hill MR, Hirani N, Maher TM, McAnulty RJ, Millar AB, Molyneaux PL, Parfrey H, Rassl DM, Whyte MKB, Fahy WA, Marshall RP, Oballa E, Bossé Y, Nickle DC, Sin DD, Timens W, Shrine N, Sayers I, Hall IP, Noth I, Schwartz DA, Tobin MD, Wain LV, Jenkins RG. A genome-wide association study for susceptibility to idiopathic pulmonary fibrosis: the effect of an AKAP13 polymorphism on disease risk. The Lancet Respir Med 2017 Nov;5(11):869-880. doi: 10.1016/S2213-2600(17)30387-9
• 27) Philp CJ, Siebeke I, Clements D, Miller S, Habgood A, John AE, Navaratnam V, Hubbard RB, Jenkins G, Johnson SR. ECM Crosslinking Enhances Fibroblast Growth and Protects Against Matrix Proteolysis in Lung Fibrosis. Am J Respir Cell Mol Biol. 2017 Oct 20. doi: 10.1165/rcmb.2016-0379OC.
• 28) Coward WR, Brand OJ, Pasini A, Jenkins G, Knox AJ, Pang L. Interplay Between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2017 Oct 20. doi: 10.1165/rcmb.2017-0286OC.
• 29) John AE, Wilson MR, Habgood A, Porte J, Tatler AL, Stavrou A, Miele G, Jolly L, Knox AJ, Takata M, Offermanns S, Jenkins RG. Loss of epithelial Gq/G11 signaling inhibits TGFβ production but promotes IL-33-mediated macrophage polarization and emphysema. Science Signaling 2016 Oct 25;9(451):ra104
• 30) Meliopoulos VA, Van de Velde LA, Van de Velde NC, Karlsson EA, Neale G, Vogel P, Guy C, Sharma S, Duan S, Surman SL, Jones BG, Johnson MD, Bosio C, Jolly L, Jenkins RG, Hurwitz JL, Rosch JW, Sheppard D, Thomas PG, Murray PJ, Schultz-Cherry S. An Epithelial Integrin Regulates the Amplitude of Protective Lung Interferon Responses against Multiple Respiratory Pathogens. PLoS Pathog. 2016; 12(8):e1005804.
• 31) Tatler AL, Goodwin AT, Gbolahan O, Saini G, Porte J, John AE, Clifford RL, Violette SM, Weinreb PH, Parfrey H, Wolters PJ, Gauldie J, Kolb M, Jenkins G. Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis. PLoS One. 2016; 11(8):e0158047.
• 32) Tatler AL, Habgood A, Porte J, John AE, Stavrou A, Hodge E, Keram-Likoko, Violette S, Weinreb P, Knox A, Laurent GJ, Parfrey H, Wolters PJ, Wallace W, Alberti S, Nordheim A, Jenkins G. Reduced Ets domain-containing protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin avb6 Expression. J Biol Chem2016; 291(18):9540-53.
• 33) Tatler AL, Barnes J, Habgood A, Goodwin A, McAnulty RJ, Jenkins G. Caffeine Inhibits TGFβ Activation in Epithelial Cells, Interrupts Fibroblast Response to TGFβ, and Reduces Established Fibrosis in Ex Vivo Precision Cut Lung Slices. Thorax 2016; 71(6):565-7.
• 34) Froese AR, Shimbori C, Bellaye PS, Inman M, Obex S, Fatima S, Jenkins G, Gauldie J, Ask K, Kolb M. Mechanical Activation of TGF-β1 in Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 Jul 1;194(1):84-96. doi: 10.1164/rccm.201508-1638OC.
• 35) Lilburn DML, Tatler AL, Six JS, Lesbats C, Habgood A, Porte J, Hughes-Riley T, Shaw DE, Jenkins G, Meersman T. Investigating lung responses with functional hyperpolarized xenon-129 MRI in an ex vivo rat model of asthma. Magnetic Res Med 2015 Oct 28. doi: 10.1002/mrm.26003.
• 36) Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R, Molyneaux PL McKeever TM, Wells AU, Flynn A, Hubbard RB, Leeming DJ, Marshall RP, Karsdal MA, Lukey PT, Maher TM. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. The Lancet Respir Med. 2015 Jun;3(6):462-72. doi: 10.1016/S2213-2600(15)00048-X. Epub 2015 Mar 12.
• 37) Saini G, Porte J, Weinreb P, Violette S, Wallace W, McKeever TM, Jenkins G. αvβ6 integrin may be a potential prognostic biomarker in Interstitial Lung Disease. Eur Resp J. 2015 Mar 5. pii: ERJ-02104-2014. [Epub ahead of print]
• 38) Porte J, Jenkins G. Assessment of the effect of potential antifibrotic compounds on total and αVβ6 integrin-mediated TGF-β activation. Pharmacol Res Perspect. 2014 Aug;2(4):e00030. doi: 10.1002/prp2.30. Epub 2014 Jun 9.
• 39) Jolly L, Stavrou A, Vanderstoken G, Meliopoulos VA, Habgood A, Tatler AL, Porte J, Knox A, Weinreb P, Violette S, Hussell T, Kolb M, Stampfli MR, Schultz-Cherry S, Jenkins G. Influenza Promotes Collagen Deposition via αvβ6 Integrin-mediated Transforming Growth Factor β Activation. J Biol Chem. 2014 Dec 19;289(51):35246-63. doi: 10.1074/jbc.M114.582262. Epub 2014 Oct 22.
• 40) John AE, Luckett JC, Tatler AL, Awais RO, Desai A, Habgood A, Ludbrook S, Blanchard AD, Perkins AC, Jenkins RG*, Marshall JF*. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med. 2013 Dec;54(12):2146-52. doi: 10.2967/jnumed.113.120592. Epub 2013 Oct 28.